Gene Therapy: Charting a Future Course—Summary of a National Institutes of Health Workshop, April 12, 2013
Abstract
Recently, the gene therapy field has begun to experience clinical successes in a number of different diseases using various approaches and vectors. The workshop Gene Therapy: Charting a Future Course, sponsored by the National Institutes of Health (NIH) Office of Biotechnology Activities, brought together early and mid-career researchers to discuss the key scientific challenges and opportunities, ethical and communication issues, and NIH and foundation resources available to facilitate further clinical advances.
Get full access to this article
View all available purchase options and get full access to this article.
References
Aiuti A., Cattaneo F., Galimberti S., et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360, 448–458.
Asokan A., and Samulski R.J. (2013). An emerging adeno-associated viral vector pipeline for cardiac gene therapy. Hum. Gene Ther. 24, 906–913.
Asokan A., Schaffer D., and Samulski R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.
Booth C., Gaspar H.B., and Thrasher A. (2011). Gene therapy for primary immunodeficiency. Curr. Opin. Pediatr. 23, 659–666.
Boye S.E., Boye S.L., Pang J., et al. (2010). Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. PLoS One 5, e11306.
Boye S.L., Conlon T., Erger K., et al. (2011). Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest. Ophthalmol. Vis. Sci. 52, 7098–7108.
Boye S.E., Alexander J.J., Boye S.L., et al. (2012). The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. Hum. Gene Ther. 23, 1101–1115.
Boye S.L., Peshenko I.V., Huang W.C., et al. (2013). AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. Hum. Gene Ther. 24, 189–202.
Candotti F., Shaw K.L., Muul L., et al. (2012). Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 120, 3635–3646.
Davila M., Riviere I., Wang X., et al. (2014). Efficacy and toxicity management of 19–28z CAR T cell therapy in a B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25.
Davis P. (2012). An unparalleled engine for discovery and clinical introduction: the clinical and translational science awards and gene therapy. Hum. Gene Ther. 23, 251–253.
Deakin C.T., Alexander I.E., and Kerridge I. (2009). Accepting risk in clinical research: is the gene therapy field becoming too risk-averse? Mol. Ther. 17, 1842–1848.
De Oliveira S.N., Ryan C., Giannoni F., et al. (2013). Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy. Hum. Gene Ther. 24, 824–839.
DiStasi A., Tey S.-K., Dotti G., et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673–1683.
Dyka F., Boye S.L., Chiodo V., et al., (2014). Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A. Hum. Gene Ther. Methods 25, 166–177.
Eshhar Z., Waks T., Gross G., et al. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90, 720–724.
Fischer A., Hacein-Bey-Abina S., and Cavazana-Calvo M. (2013). Gene therapy of primary T cell immunodeficiencies. Gene 525, 170–173.
Frantz S. (2011). Engineered T-cell therapy shows efficacy in blood cancer. Nat. Biotechnol. 29, 853–855.
Gerdemann U., Katari U., Papadopoulou A., et al. (2013). Safety and clinical efficacy of rapidly-generated trivirus–directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol. Ther. 21, 2113–2121.
Giannoni F., Hardee C.L., Wherley J., et al. (2013). Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol. Ther. 21, 1044–1054.
Gradaz Z., Hegde M., Byrd T., et al. (2013). TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy, Mal. Ther. Nuc. Acids. 2, e105.
Grupp S., Kalos M., Barrett D., et al. (2013.) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518.
Hacein-Bey-Abina S., Hauer J., Lim A., et al. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363, 355–364.
Hauswirth W., Aleman T., Kaushal S., et al. (2008). Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther. 19, 979–990.
Hegde M., Corder A., Chow K., et al. (2013). Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol. Ther. 21, 2087–2101.
Jacobson S.G., Cideciyan A.V., Peshenko I.V., et al. (2013). Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. Hum. Mol. Genet. 22, 168–183.
Kaminsky S., Rosengart T., Rosenberg J., et al. (2013). Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease. Hum. Gene Ther. 24, 948–963.
Kimmelman J. (2009). Tomorrow, interrupted? Risk, ethics, and medical advance in gene transfer. Mol. Ther. 17, 1838–1839.
Kudva Y., Ohmine S., Greder L., et al. (2012). Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. Stem Cells Trans. Med. 1, 451–461.
Liu J., Wallace M., Garwick-Coppens S., et al. (2014). RNAi-mediated gene silencing of mutant myotilin improves myopathy in LGMD1A mice. Mol. Ther. Nucleic Acids 3, e160.
Lopes V.S., Boye S.E., Louie C.M., et al. (2013). Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus. Gene Ther. 20, 824–833.
Maguire A., Simonelli F., Pierce E., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240–2248.
Mukherjee S., and Thrasher A. (2013). Gene therapy for PIDs: progress, pitfalls, and prospects. Gene 525, 174–181.
Nathwani A.C., Tuddenham E., Rangarajan S., et al. (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357–2365.
Porter D., Levine B., Kalos M., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733.
Pule M., Finney H., andLawson A., et al. (2003). Artificial T cell receptors. Cytotherapy 5, 211–226.
Pule M., Savoldo B., Myers G.D., et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264–1270.
Romero Z., Urbinati F., Geiger S., et al. (2013). β-globin gene transfer to human bone marrow for sickle cell disease. J. Clin. Invest. 123, 3317–3330.
Savoldo B., Ramos C., Liu E., et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822–1826.
Sondhi D., Johnson L., Purpura K., et al. (2012). Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Hum. Gene Ther. Methods 23, 324–335.
Stroes E., Nieman M., Meulenberg J., et al. (2008). Intramuscular administration of AAV1-lipoprotein lipaseS447× lowers triglycerides in lipoprotein lipase-deficient patients. Arterioschler. Thromb. Vasc. Biol. 28, 2303–2304.
Thatava T., Kudva Y., Edukulla R., et al. (2013). Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells. Mol. Ther. 21, 228–239.
Till B., Jensen M., Wang J., et al. (2013). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4–1 BB domains: pilot clinical trial results. Blood 119, 3940–3950.
VandenDriessche T., and Chuah M.K. (2012). Clinical progress in gene therapy: sustained partial correction of the bleeding disorder in patients suffering from severe hemophilia B. Hum. Gene Ther. 23, 4–6.
Vanneman M., and Dranoff G. (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237–251.
Wade N. (2011). Treatment of blood disease is gene therapy landmark. New York Times, December 11.
Zallin D. (2000). US gene therapy in crisis. Trends Genet. 6, 272–275.
Information & Authors
Information
Published In
Copyright
Copyright 2014, Mary Ann Liebert, Inc.
History
Published in print: June 2014
Published online: 28 April 2014
Accepted: 22 April 2014
Received: 21 April 2014
Topics
Authors
Author Disclosure Statement
M.O'R., J.C.C., E.R., R.J., L.G., M.M., A.P.P., L.P., M.A., T.W., B.T., A.A., S.E.B., S.D.O., D.B.K., Y.I., J.A., S.Q.H., M.S.E., R.C., J.G., L.P., C.L.M., R.G.-S., D.R., P.A., D.H.S., W.W., W.F.G., and L.Z. have no competing financial interests.
N.A. has patent applications in the field of T-cell and gene-modified T-cell therapy for cancer. The Center for Cell and Gene Therapy (CAGT) has research collaboration with Celgene Inc. to develop CAR-based therapeutics that is administered by Baylor College of Medicine. L.H.V. is inventor on gene therapy–related patents that are licensed to various pharmaceutical and biotechnological companies, holds equity in GenSight Biologics, consults for Novartis and GenSight Biologics, and receives funding from the Foundation Fighting Blindness and the Massachusetts Eye and Ear Infirmary (Boston, MA). He has been employed by the University of Pennsylvania and the Massachusetts Eye and Ear Infirmary. Y.F. is a paid advisor for Genelux and consultant to Roche. H.F. is a founder and advisor to MedGenesis. P.M.'s university receives or has received funding to support basic science research work in the author's laboratory from Asklepios Biopharmaceutical and Baxter Biologics. He has received remuneration for consulting work and for speaking from Asklepios Biopharmaceutical and Baxter Biologics.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.